AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
AbbVie total assets
Total assets on the balance sheet at the end of each period.
AbbVie's total assets was $135.12B at Jun 30, 2026. For fiscal 2025 it was $133.96B, down 0.9% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $150.57B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.96B | -0.9% |
| FY2024 | Dec 31, 2024 | $135.16B | +0.3% |
| FY2023 | Dec 31, 2023 | $134.71B | -2.9% |
| FY2022 | Dec 31, 2022 | $138.81B | -5.3% |
| FY2021 | Dec 31, 2021 | $146.53B | -2.7% |
| FY2020 | Dec 31, 2020 | $150.57B | +69.0% |
| FY2019 | Dec 31, 2019 | $89.12B | +50.1% |
| FY2018 | Dec 31, 2018 | $59.35B | -16.2% |
| FY2017 | Dec 31, 2017 | $70.79B | +7.1% |
| FY2016 | Dec 31, 2016 | $66.10B | +24.6% |
| FY2015 | Dec 31, 2015 | $53.05B | +92.8% |
| FY2014 | Dec 31, 2014 | $27.51B | -5.8% |
| FY2013 | Dec 31, 2013 | $29.20B | +8.1% |
| FY2012 | Dec 31, 2012 | $27.01B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $135.12B | -1.5% |
| Q1 FY2026 | Mar 31, 2026 | $136.46B | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | $133.96B | -0.9% |
| Q3 FY2025 | Sep 30, 2025 | $133.90B | -6.6% |
| Q2 FY2025 | Jun 30, 2025 | $137.18B | -3.4% |
| Q1 FY2025 | Mar 31, 2025 | $136.17B | -8.5% |
| Q4 FY2024 | Dec 31, 2024 | $135.16B | +0.3% |
| Q3 FY2024 | Sep 30, 2024 | $143.42B | +5.3% |
| Q2 FY2024 | Jun 30, 2024 | $141.94B | +4.9% |
| Q1 FY2024 | Mar 31, 2024 | $148.87B | +10.7% |
| Q4 FY2023 | Dec 31, 2023 | $134.71B | -2.9% |
| Q3 FY2023 | Sep 30, 2023 | $136.22B | -3.6% |
| Q2 FY2023 | Jun 30, 2023 | $135.37B | -5.5% |
| Q1 FY2023 | Mar 31, 2023 | $134.54B | -6.1% |
| Q4 FY2022 | Dec 31, 2022 | $138.81B | -5.3% |
| Q3 FY2022 | Sep 30, 2022 | $141.33B | -5.1% |
| Q2 FY2022 | Jun 30, 2022 | $143.19B | -3.2% |
| Q1 FY2022 | Mar 31, 2022 | $143.21B | -4.8% |
| Q4 FY2021 | Dec 31, 2021 | $146.53B | -2.7% |
| Q3 FY2021 | Sep 30, 2021 | $148.86B | -0.5% |
| Q2 FY2021 | Jun 30, 2021 | $147.97B | -1.0% |
| Q1 FY2021 | Mar 31, 2021 | $150.50B | +65.0% |
| Q4 FY2020 | Dec 31, 2020 | $150.57B | +69.0% |
| Q3 FY2020 | Sep 30, 2020 | $149.62B | +151.7% |
| Q2 FY2020 | Jun 30, 2020 | $149.53B | +161.7% |
| Q1 FY2020 | Mar 31, 2020 | $91.20B | +60.6% |
| Q4 FY2019 | Dec 31, 2019 | $89.12B | +50.1% |
| Q3 FY2019 | Sep 30, 2019 | $59.44B | -10.2% |
| Q2 FY2019 | Jun 30, 2019 | $57.14B | -7.3% |
| Q1 FY2019 | Mar 31, 2019 | $56.77B | -18.1% |
| Q4 FY2018 | Dec 31, 2018 | $59.35B | -16.2% |
| Q3 FY2018 | Sep 30, 2018 | $66.16B | -3.9% |
| Q2 FY2018 | Jun 30, 2018 | $61.64B | -8.0% |
| Q1 FY2018 | Mar 31, 2018 | $69.34B | +5.6% |
| Q4 FY2017 | Dec 31, 2017 | $70.79B | +7.1% |
| Q3 FY2017 | Sep 30, 2017 | $68.84B | +3.3% |
| Q2 FY2017 | Jun 30, 2017 | $66.99B | – |
| Q1 FY2017 | Mar 31, 2017 | $65.66B | – |
| Q4 FY2016 | Dec 31, 2016 | $66.10B | – |
| Q3 FY2016 | Sep 30, 2016 | $66.63B | – |
See a number that looks wrong?